Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Testosterone synthesis]

Mikio Namiki1, Eitetsu Koh, Atsushi Mizokami

  • 1Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Sciences.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|May 13, 2006
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Lowest PSA Level Achieved Before CRPC Predicts Abiraterone Response But Not Enzalutamide Response in Metastatic CRPC.

The Prostate·2026
Same author

Comparison of automated bone scan indexes in patients with prostate cancer: aBSI and BONENAVI.

Annals of nuclear medicine·2026
Same author

Efficacy of Testosterone Replacement Therapy Combined With Exercise on Body Composition in Hypogonadal Men.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Prostate-Specific Membrane Antigen Positron Emission Tomography in Japan: An Implementation Gap in the Era of Global Adoption.

Asia-Pacific journal of clinical oncology·2026
Same author

Efficacy and Safety of Enzalutamide and Abiraterone in CRPC Patients With a History of Other Cancers: A Sub-Analysis of the ENABLE Study for PCa.

International journal of urology : official journal of the Japanese Urological Association·2026
Same author

Fibroblast-mediated KRAS activation in double-negative prostate cancer.

Cell death & disease·2026